Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer

E. S. Antonarakis, A. J. Armstrong

Research output: Contribution to journalReview article

Abstract

Although treatment options for men with castration-resistant prostate cancer (CRPC) have improved with the recent and anticipated approvals of novel immunotherapeutic, hormonal, chemotherapeutic and bone-targeted agents, clinical benefit with these systemic therapies is transient and survival times remain unacceptably short. Thus, we devote the second section of this two-part review to discussing emerging therapeutic paradigms and research strategies that are entering phase II and III clinical testing for men with metastatic CRPC. We will discuss a range of emerging hormonal, immunomodulatory, antiangiogenic, epigenetic and cell survival pathway inhibitors in current clinical trials, with an emphasis on how these therapies may complement our existing treatment options.

Original languageEnglish (US)
Pages (from-to)206-218
Number of pages13
JournalProstate Cancer and Prostatic Diseases
Volume14
Issue number3
DOIs
StatePublished - Sep 1 2011

Keywords

  • castrate-resistant prostate cancer
  • clinical trials
  • drug development
  • novel therapies

ASJC Scopus subject areas

  • Oncology
  • Urology
  • Cancer Research

Fingerprint Dive into the research topics of 'Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer'. Together they form a unique fingerprint.

  • Cite this